These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 12780795)
1. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Gruel Y; Pouplard C; Nguyen P; Borg JY; Derlon A; Juhan-Vague I; Regnault V; Samama M; Br J Haematol; 2003 Jun; 121(5):786-92. PubMed ID: 12780795 [TBL] [Abstract][Full Text] [Related]
2. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Pouplard C; May MA; Iochmann S; Amiral J; Vissac AM; Marchand M; Gruel Y Circulation; 1999 May; 99(19):2530-6. PubMed ID: 10330384 [TBL] [Abstract][Full Text] [Related]
4. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Lubenow N; Hinz P; Thomaschewski S; Lietz T; Vogler M; Ladwig A; Jünger M; Nauck M; Schellong S; Wander K; Engel G; Ekkernkamp A; Greinacher A Blood; 2010 Mar; 115(9):1797-803. PubMed ID: 19965682 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Ahmad S; Haas S; Hoppensteadt DA; Lietz H; Reid U; Bender N; Messmore HL; Misselwitz F; Bacher P; Gaikwad BS; Jeske WP; Walenga JM; Fareed J Thromb Res; 2002 Oct; 108(1):49-55. PubMed ID: 12586132 [TBL] [Abstract][Full Text] [Related]
6. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
7. A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Padmanabhan A; Jones CG; Curtis BR; Bougie DW; Sullivan MJ; Peswani N; McFarland JG; Eastwood D; Wang D; Aster RH Chest; 2016 Sep; 150(3):506-15. PubMed ID: 26905366 [TBL] [Abstract][Full Text] [Related]
8. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. Fabris F; Luzzatto G; Soini B; Ramon R; Scandellari R; Randi ML; Girolami A J Intern Med; 2002 Aug; 252(2):149-54. PubMed ID: 12190890 [TBL] [Abstract][Full Text] [Related]
10. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. Visentin GP; Malik M; Cyganiak KA; Aster RH J Lab Clin Med; 1996 Oct; 128(4):376-83. PubMed ID: 8833886 [TBL] [Abstract][Full Text] [Related]
12. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Warkentin TE; Sheppard JA; Horsewood P; Simpson PJ; Moore JC; Kelton JG Blood; 2000 Sep; 96(5):1703-8. PubMed ID: 10961867 [TBL] [Abstract][Full Text] [Related]
13. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Lindhoff-Last E; Nakov R; Misselwitz F; Breddin HK; Bauersachs R Br J Haematol; 2002 Sep; 118(4):1137-42. PubMed ID: 12199798 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Matsuo T; Wanaka K; Walenga JM Clin Appl Thromb Hemost; 2013; 19(1):73-8. PubMed ID: 22345486 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine. Mattioli AV Semin Thromb Hemost; 2004 Jun; 30(3):291-5. PubMed ID: 15282651 [TBL] [Abstract][Full Text] [Related]
16. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Walenga JM; Jeske WP; Prechel MM; Bacher P; Bakhos M Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():69-80. PubMed ID: 15085468 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Warkentin TE; Davidson BL; Büller HR; Gallus A; Gent M; Lensing AWA; Piovella F; Prins MH; Segers AEM; Kelton JG Chest; 2011 Aug; 140(2):366-373. PubMed ID: 21393394 [TBL] [Abstract][Full Text] [Related]
19. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Warkentin TE; Greinacher A Chest; 2004 Sep; 126(3 Suppl):311S-337S. PubMed ID: 15383477 [TBL] [Abstract][Full Text] [Related]
20. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Demma LJ; Winkler AM; Levy JH Anesth Analg; 2011 Oct; 113(4):697-702. PubMed ID: 21788317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]